Novocure Launches 31% After Pancreatic Cancer Treatment Succeeds
Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer.